Boston Scientific Corporation $BSX Position Lessened by Gradient Investments LLC

Gradient Investments LLC cut its stake in shares of Boston Scientific Corporation (NYSE:BSX) by 5.3% in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 443,592 shares of the medical equipment provider’s stock after selling 24,743 shares during the quarter. Gradient Investments LLC’s holdings in Boston Scientific were worth $19,363,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds have also recently added to or reduced their stakes in the company. Avidian Wealth Enterprises LLC boosted its stake in Boston Scientific by 372.9% in the third quarter. Avidian Wealth Enterprises LLC now owns 31,451 shares of the medical equipment provider’s stock worth $1,373,000 after buying an additional 24,801 shares in the last quarter. Quintet Private Bank Europe S.A. lifted its holdings in shares of Boston Scientific by 91.4% in the 3rd quarter. Quintet Private Bank Europe S.A. now owns 20,500 shares of the medical equipment provider’s stock worth $895,000 after acquiring an additional 9,787 shares during the last quarter. Venture Visionary Partners LLC boosted its stake in shares of Boston Scientific by 10.2% in the 3rd quarter. Venture Visionary Partners LLC now owns 12,606 shares of the medical equipment provider’s stock valued at $550,000 after purchasing an additional 1,168 shares in the last quarter. Elevation Wealth Partners LLC grew its holdings in shares of Boston Scientific by 364.4% during the 3rd quarter. Elevation Wealth Partners LLC now owns 1,082 shares of the medical equipment provider’s stock valued at $47,000 after purchasing an additional 849 shares during the last quarter. Finally, Canandaigua National Bank & Trust Co. bought a new position in shares of Boston Scientific during the 3rd quarter valued at $506,000. Institutional investors own 89.07% of the company’s stock.

Insider Buying and Selling at Boston Scientific

In related news, Director Edward Ludwig acquired 5,000 shares of the firm’s stock in a transaction on Friday, July 31st. The stock was acquired at an average cost of $45.48 per share, for a total transaction of $227,400.00. Following the acquisition, the director owned 30,359 shares of the company’s stock, valued at $1,380,727.32. This trade represents a 19.72% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which is available at this link. Also, Director David Habiger bought 2,100 shares of the company’s stock in a transaction dated Wednesday, August 5th. The stock was bought at an average cost of $47.59 per share, with a total value of $99,939.00. Following the completion of the transaction, the director owned 17,160 shares in the company, valued at approximately $816,644.40. This trade represents a 13.94% increase in their position. The disclosure for this purchase is available in the SEC filing. In the last ninety days, insiders have purchased 194,522 shares of company stock valued at $9,385,210. 0.34% of the stock is currently owned by company insiders.

Analyst Ratings Changes

Several research firms have weighed in on BSX. Stifel Nicolaus set a $60.00 price target on shares of Boston Scientific in a research note on Wednesday, July 29th. Oppenheimer lowered their target price on Boston Scientific from $85.00 to $65.00 and set an “outperform” rating for the company in a research note on Monday, September 21st. Wall Street Zen lowered Boston Scientific from a “buy” rating to a “hold” rating in a research report on Sunday, August 2nd. Wells Fargo & Company decreased their price target on Boston Scientific from $50.00 to $48.00 and set an “equal weight” rating on the stock in a research note on Wednesday, September 23rd. Finally, Robert W. Baird set a $56.00 price objective on Boston Scientific in a research report on Thursday, July 30th. Twenty-two investment analysts have rated the stock with a Buy rating, six have issued a Hold rating and two have issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $66.31.

Key Stories Impacting Boston Scientific

Here are the key news stories impacting Boston Scientific this week:

• Positive Sentiment: Boston Scientific appointed longtime cardiovascular executive Joseph M. Fitzgerald as executive vice president and chief operating officer and reorganized its operations into three segments. Management said the structure is intended to improve efficiency and support continued growth, which could strengthen execution over time. Boston Scientific appoints Joseph M. Fitzgerald Executive Vice President and Chief Operating Officer
• Neutral Sentiment: Barclays initiated coverage of Boston Scientific with an “equal weight” rating, later described as “hold.” The stance suggests the firm sees a balanced risk-reward profile rather than a clear catalyst for significant near-term appreciation. Barclays initiates coverage of Boston Scientific with equal-weight
• Neutral Sentiment: Boston Scientific is attracting increased attention from Zacks users, but the report does not identify a new earnings surprise or material fundamental change. The company’s latest reported quarter exceeded consensus estimates, although current trading is being driven more by sentiment and analyst commentary. Boston Scientific Corporation is Attracting Investor Attention
• Negative Sentiment: Shares fell to a new one-year low near $41.50, signaling continued technical weakness. The stock is trading well below its 50-day and 200-day moving averages, which can encourage additional selling and reflects investor concern despite the company’s longer-term growth prospects. Boston Scientific Reaches New 1-Year Low
• Negative Sentiment: Citigroup issued a pessimistic forecast for BSX, adding to the negative analyst tone surrounding the stock. The bearish outlook, combined with the new low and Barclays’ lack of a buy rating, is likely weighing on investor confidence. Citigroup Issues Pessimistic Forecast for Boston Scientific

Boston Scientific Trading Up 0.2%

NYSE:BSX traded up $0.08 during mid-day trading on Thursday, reaching $41.66. 7,215,731 shares of the company’s stock traded hands, compared to its average volume of 18,643,260. The company has a 50 day moving average price of $46.72 and a 200-day moving average price of $50.90. The firm has a market capitalization of $60.37 billion, a price-to-earnings ratio of 16.90, a PEG ratio of 1.01 and a beta of 0.58. The company has a debt-to-equity ratio of 0.43, a current ratio of 1.24 and a quick ratio of 0.74. Boston Scientific Corporation has a 12-month low of $41.44 and a 12-month high of $105.65.

Boston Scientific (NYSE:BSX) last issued its quarterly earnings data on Wednesday, July 29th. The medical equipment provider reported $0.86 earnings per share for the quarter, topping analysts’ consensus estimates of $0.83 by $0.03. The firm had revenue of $5.44 billion for the quarter, compared to analyst estimates of $5.38 billion. Boston Scientific had a return on equity of 19.28% and a net margin of 17.50%.The business’s quarterly revenue was up 7.5% compared to the same quarter last year. During the same period last year, the company earned $0.75 EPS. Boston Scientific has set its Q3 2026 guidance at 0.800-0.820 EPS and its FY 2026 guidance at 3.280-3.320 EPS. On average, sell-side analysts predict that Boston Scientific Corporation will post 3.25 earnings per share for the current year.

About Boston Scientific

Boston Scientific Corporation is a global medical technology company that develops, manufactures and markets devices used to diagnose and treat a broad range of medical conditions. Its products are designed to support minimally invasive procedures across areas including cardiovascular care, endoscopy, urology, pelvic health and neuromodulation.

The company’s portfolio includes devices for interventional cardiology and peripheral interventions, electrophysiology and cardiac rhythm management, gastrointestinal and pulmonary procedures, kidney stone and prostate treatments, urinary and pelvic health, and chronic pain management.